PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-19.03%
Negative revenue growth while MRVL stands at 4.78%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-70.57%
Negative gross profit growth while MRVL is at 3.56%. Joel Greenblatt would examine cost competitiveness or demand decline.
-218.87%
Negative EBIT growth while MRVL is at 4.64%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-218.87%
Negative operating income growth while MRVL is at 4.64%. Joel Greenblatt would press for urgent turnaround measures.
-202.45%
Negative net income growth while MRVL stands at 6.81%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-203.33%
Negative EPS growth while MRVL is at 6.25%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-206.90%
Negative diluted EPS growth while MRVL is at 10.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.98%
Share count expansion well above MRVL's 1.11%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-3.09%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
736.35%
OCF growth above 1.5x MRVL's 24.90%. David Dodd would confirm a clear edge in underlying cash generation.
85.32%
FCF growth above 1.5x MRVL's 23.14%. David Dodd would verify if the firm’s strategic investments yield superior returns.
544.50%
10Y revenue/share CAGR at 50-75% of MRVL's 844.36%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
24.88%
5Y revenue/share CAGR under 50% of MRVL's 99.06%. Michael Burry would suspect a significant competitive gap or product weakness.
-17.12%
Negative 3Y CAGR while MRVL stands at 23.77%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
93.19%
10Y OCF/share CAGR under 50% of MRVL's 4026.67%. Michael Burry would worry about a persistent underperformance in cash creation.
-35.81%
Negative 5Y OCF/share CAGR while MRVL is at 146.83%. Joel Greenblatt would question the firm’s operational model or cost structure.
-90.09%
Negative 3Y OCF/share CAGR while MRVL stands at 545.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-947.31%
Negative 10Y net income/share CAGR while MRVL is at 11837.55%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-266.67%
Negative 5Y net income/share CAGR while MRVL is 146.49%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-177.98%
Negative 3Y CAGR while MRVL is 452.95%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1713.37%
10Y equity/share CAGR 1.25-1.5x MRVL's 1151.86%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
91.55%
5Y equity/share CAGR above 1.5x MRVL's 60.58%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
16.70%
Below 50% of MRVL's 39.98%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.25%
Firm’s AR is declining while MRVL shows 9.37%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
11.87%
Inventory growth well above MRVL's 15.81%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-1.89%
Negative asset growth while MRVL invests at 7.06%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.44%
We have a declining book value while MRVL shows 4.86%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-1.51%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-3.42%
Our R&D shrinks while MRVL invests at 4.15%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
8.79%
SG&A growth well above MRVL's 1.25%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.